SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The revenue zoomed 13.01% to Rs. 10965.73 millions for the quarter ended June 2025 as compared to Rs. 9702.93 millions during the corresponding quarter last year.The Total revenue for the quarter ended June 2025 of  Rs. 1227.89  millions  grew by 203.59% from Rs. 404.46 millions.Operating Profit saw a handsome growth to 2495.24 millions from 1476.94 millions in the quarter ended June 2025.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202506 202406 % Var 202506 202406 % Var 202503 202403 % Var
Sales 10965.73 9702.93 13.01 10965.73 9702.93 13.01 43819.24 34976.55 25.28
Other Income 215.24 279.43 -22.97 215.24 279.43 -22.97 1188.07 1262.36 -5.89
PBIDT 2495.24 1476.94 68.95 2495.24 1476.94 68.95 7656.44 5801.51 31.97
Interest 205.38 375.67 -45.33 205.38 375.67 -45.33 1129.62 1660.92 -31.99
PBDT 2254.86 1101.27 104.75 2254.86 1101.27 104.75 6526.82 4047.44 61.26
Depreciation 598.17 550.79 8.60 598.17 550.79 8.60 2249.72 2048.32 9.83
PBT 1656.69 550.48 200.95 1656.69 550.48 200.95 4277.10 1999.12 113.95
TAX 428.80 146.02 193.66 428.80 146.02 193.66 1105.82 390.78 182.98
Deferred Tax -11.23 16.89 -166.49 -11.23 16.89 -166.49 -21.25 4.97 -527.57
PAT 1227.89 404.46 203.59 1227.89 404.46 203.59 3171.28 1608.34 97.18
Equity 1895.08 1811.52 4.61 1895.08 1811.52 4.61 1894.83 1811.52 4.60
PBIDTM(%) 22.75 15.22 49.49 22.75 15.22 49.49 17.47 16.59 5.34

Emcure Pharma Share Price

1813.00 5.20 (0.29%)
10-Jul-2026 14:02 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1929.40
Dr. Reddys Labs. 1244.65
Cipla 1439.80
Zydus Lifesciences 1148.75
Lupin 2496.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: